Granules India Limited

50.9%

and EBITDA margins (Rs. Mn.) 8 6 9 , 9 0 0 3 , 0 1 6 9 1 , 0 1 3 8 8 , 8 7 0 5 , 1 1 5,722 50.9% 4,517 4,648 46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1

46.6%

. Mn.) 8 6 9 , 9 0 0 3 , 0 1 6 9 1 , 0 1 3 8 8 , 8 7 0 5 , 1 1 5,722 50.9% 4,517 4,648 46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1%

48.9%

3 , 0 1 6 9 1 , 0 1 3 8 8 , 8 7 0 5 , 1 1 5,722 50.9% 4,517 4,648 46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 2

49.6%

6 9 1 , 0 1 3 8 8 , 8 7 0 5 , 1 1 5,722 50.9% 4,517 4,648 46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 20.7% 2

49.7%

, 0 1 3 8 8 , 8 7 0 5 , 1 1 5,722 50.9% 4,517 4,648 46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 20.7% 21.1% 1

17.0%

7 0 5 , 1 1 5,722 50.9% 4,517 4,648 46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 20.7% 21.1% 17.4% Q2FY22 Q3FY2

17.4%

4,517 4,648 46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 20.7% 21.1% 17.4% Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY2

18.7%

4,648 46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 20.7% 21.1% 17.4% Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY2

25.1%

46.6% 5,039 5,060 48.9% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 20.7% 21.1% 17.4% Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY2

20.7%

% 49.6% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 20.7% 21.1% 17.4% Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY2

21.1%

% 49.7% 2 1 5 , 1 17.0% 7 3 7 , 1 7 2 9 , 1 17.4% 18.7% 25.1% 9 2 4 , 2 5 1 1 , 2 20.7% 21.1% 17.4% Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY2

16%

e v e R Growth in USA due to higher Paracetamol sales Finished Dosage, PFI and API segments grew 16%, 23% and 73% Q2FY22 4.2% Q2FY23 4.9% 5.5% 53.8% 7.1% 20.2% 57.8% 11.0% 7.1% 20.4% 3.4%

As Encl

1

Total GPI products include

1

Corporate address

1

As Encl

(Hyderabad! N y / a CHAITANYA TUMMALADigitally signed by CHAITANYA TUMMALA DN: c=IN, o=PERSONAL, title=1722, pseudonym=5a1421da00444714ae97e87640a0419e, 2.5.4.20=f7feec72a52be0b16d0827d9d73aa615bad9538180242f5bb3efe11f1a5fd10d, postalCode=500013, st=TELANGANA, serialNumber=ae6c5085a4c307805711d3f1ab8a1ff2da48346a26aa5fe898e52ec0775c3c69, cn=CHAITANYA TUMMALA Date: 2022.10.20 13:16:07 +05'30' Granules India Limited Q2FY23 Earnings Presentation 1 Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctne

Total GPI products include

ANDA/Dossier filed - Therapeutic area wise CII – 8 PFOS – 4 Liquid Orals – 3 Analgesics Central Nervous System Anti-diabetics Mineral supplements 5 Cardiovascular Anti-Histamines 4 Anti-gout Antitussives Other areas 3 3 8 7 24 19 12 7 Revenue trend – percentage share from Core and Other Molecules Core Others Para MF IBU GGF MCB Others 14% 14% 17% 14% 15% 17% 16% 15% 19% 16% 86% 86% 83% 86% 85% 83% 84% 85% 81% 84% 14% 34% 1% 5% 17% 29% 33% 17% 26% 6% 4% 19% 21% 21% 34% 29% 34% 34% 33% 30% 15% 18% 5% 3% 25% 19% 23% 17% 29% 14% 16% 3% 3% 3% 18% 16% 19% 3% 3% 13% 3% 6% 26% 25% 17% 4% 5% 5% 1% 14% 34% 38% 3% 14% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Core includes Paracetamol, Metformin, Ibuprofen, Methocarbamol and Guaifenesin 8 5-year trajectory: Key Ratios and Cash Flow (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) 9,082 8,704 3.1 6,138 2.1 6,058 5,752 2.4 6,966 135 125 138 114 109 117 2,919 1,615 1.2 1.0 0.7 Mar-17 Mar-18 Mar-19 Ma

Corporate address

Floor 2 Block 3 My Home Hub Madhapur Hyderabad 500081 CIN: L24110TG1991PLC012471 Voice: +91 40 69043600 www.granulesindia.com 532482 GRANULES GRAN:IN GRAN:NS